Brainsway Ltd. Sponsored ADR (BWAY) Hits Fresh High: Is There Still Room to Run?

Brainsway Ltd. Sponsored ADR (BWAY) recently hit a new 52-week high, driven by consistent earnings beats, with the latest EPS surpassing estimates by $0.02. The stock has gained 24.4% year-to-date, outperforming the Zacks Medical sector, and is projected to increase revenues by 22.78% this fiscal year and 19.78% the next; despite trading at a premium to its peers, Brainsway holds a Zacks Rank #2 (Buy), suggesting potential for further gains, while Phibro Animal Health Corporation (PAHC) is presented as another strong performer in the same industry.

Analysis

Brainsway Ltd. (BWAY) has exhibited robust stock performance, achieving a new 52-week high of $12, reflecting a 14.2% gain over the past month and a 24.4% year-to-date increase. This significantly outpaces the Zacks Medical sector's -2.4% decline and the Zacks Medical - Products industry's 5.7% return. The company's outperformance is supported by a consistent history of positive earnings surprises, having surpassed consensus estimates in each of the last four quarters. Notably, in its May 13, 2025 earnings report, Brainsway announced an EPS of $0.04, double the $0.02 consensus, and exceeded revenue estimates by 2.03%. For the current fiscal year, Brainsway is projected to achieve revenues of $50.36 million, a 22.78% increase, though EPS is expected to be $0.15, a -16.67% change. However, a strong rebound is anticipated for the next fiscal year, with projected EPS of $0.24 (a 60% year-over-year increase) and revenues of $60.32 million (a 19.78% year-over-year increase). While Brainsway boasts a Zacks Growth Score of A and a VGM Score of B, its valuation metrics indicate a significant premium; it trades at 76.9 times current fiscal year EPS estimates and 47 times trailing cash flow, compared to industry averages of 19.4X and 11.4X respectively, earning it a Value Score of C. Despite this premium, favorable earnings estimate revisions have resulted in a Zacks Rank of #2 (Buy), suggesting further potential upside. The article also notes Phibro Animal Health Corporation (PAHC) as a strong peer with a Zacks Rank #1 (Strong Buy) and more attractive valuation multiples.

Key Decisions for Investors

• Investors may find Brainsway's strong growth trajectory and consistent earnings beats appealing, particularly given its Zacks Rank #2 (Buy) and A-grade Growth Score, suggesting continued momentum is possible.
• Careful consideration should be given to Brainsway's high valuation multiples; continued robust earnings growth and operational execution will be crucial to justify the current premium over industry peers.
• Monitor upcoming earnings reports closely, especially focusing on the projected 60% EPS growth in the next fiscal year, as this is a key driver for the bullish outlook despite the current year's anticipated EPS decline and high valuation.